Based on the in vitro data and biodistribution studies, the NF9006 tumor mouse model appeared useful to investigate the potential of [177Lu]Lu-DOTA-folate to enhance anti-CTLA-4 immunotherapy. This evidence concerns the gene CTLA4 and neoplasm.